OpenAI and NVIDIA Join the 'AI Drug' Race... K-Bio Stands Out Amid Big Pharma Alliances

The alliance between global big tech companies and major pharmaceutical firms (big pharma) for artificial intelligence (AI)-driven drug development is becoming increasingly robust. Since the joint AI drug development investment of 1 billion dollars (approximately 1.4723 trillion won) carried out by Eli Lilly and NVIDIA earlier this year, cross-industry collaborations that break down traditional boundaries have become a full-fledged trend.

According to the global pharmaceutical and IT industries as of April 21, the combination of big tech-equipped with massive computational infrastructure-and big pharma, which possesses vast clinical data, is accelerating the entire process of drug development. This collaboration shortens the timeline from candidate substance discovery to clinical trial design. It is serving as a key driver for overcoming the limitations of traditional drug research and development (R&D), which required astronomical costs and over a decade of time, and is making cost reductions across the industry increasingly visible.

원본보기 아이콘

Major AI companies are launching models specialized for life sciences one after another, intensifying the competition for leadership. Novo Nordisk, which is fiercely competing in the obesity treatment market, has partnered with OpenAI to introduce AI into its drug development processes. Through its strategic partnership with OpenAI, Novo Nordisk aims to rapidly process complex data and significantly reduce the time required from drug research to actual patient treatment. The company plans to first apply AI experimentally to its drug R&D sector, then expand its application to all areas of the company-including production and distribution-by the end of this year.

AI company Anthropic recently appointed Vasant Narasimhan, CEO of Novartis, as a new board director. With the addition of Narasimhan, an expert in public health and medical fields, Anthropic is expected to accelerate the expansion of its healthcare business. Anthropic is already expanding its collaborations with global big pharma firms such as Eli Lilly and Novo Nordisk and has recently increased its healthcare investments, including the acquisition of life science startup Coefficient Bio.

As these alliances between big tech and big pharma accelerate, the core competitive edge in the global market is being reorganized around AI capabilities. With the combination of specialized infrastructure provided by companies like NVIDIA and OpenAI and the accumulated data of pharmaceutical companies, AI has become more than just an auxiliary tool-it has established itself as the core platform for drug development. In addition to reducing initial development costs, AI is demonstrating visible economic effects by lowering the probability of failure and increasing new drug approval rates, suggesting that large-scale investment by related companies will likely continue.

Amid this wave of global collaboration, South Korean bio companies are also gaining recognition for their achievements in AI-driven drug research on the international stage. Galux, a domestic AI drug development firm, drew attention at the American Association for Cancer Research (AACR 2026), held in San Diego, USA, through April 22, by presenting preclinical efficacy data for its AI-designed bispecific antibody drug candidate. Galux’s candidate was developed to minimize the systemic toxic side effects pointed out as a limitation of existing immuno-oncology drugs and to act selectively only within the tumor microenvironment. Animal test results confirmed more than 90% inhibition of tumor growth in refractory tumor models unresponsive to immuno-oncology drugs, demonstrating Galux’s independent AI drug design and validation capabilities.

An industry representative stated, "As the capital and infrastructure of big tech, the accumulated expertise of big pharma, and the innovative technological capabilities of bio companies organically converge, the pace of AI-driven drug commercialization is expected to accelerate even further."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.